{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:51:07Z","timestamp":1761789067799,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.sleep.2012.08.019","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T22:16:36Z","timestamp":1349907396000},"page":"1313-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome"],"prefix":"10.1016","volume":"13","author":[{"given":"Imad","family":"Ghorayeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Vivot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Tison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Burbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.sleep.2012.08.019_b0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.sleep.2012.08.019_b0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.smrv.2009.11.006","article-title":"Dopaminergic augmentation of restless legs syndrome","volume":"14","author":"Garcia-Borreguero","year":"2010","journal-title":"Sleep Med Rev"},{"issue":"12","key":"10.1016\/j.sleep.2012.08.019_b0015","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/jnnp.2010.211417","article-title":"Poor effect of guideline based treatment of restless legs syndrome in clinical practice","volume":"81","author":"Godau","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.sleep.2012.08.019_b0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2377-10-86","article-title":"Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch","volume":"10","author":"Hogl","year":"2010","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.sleep.2012.08.019_b0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"issue":"12","key":"10.1016\/j.sleep.2012.08.019_b0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ncpneuro0948","article-title":"Botulinum neurotoxins in the treatment of refractory pain","volume":"4","author":"Jabbari","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"Pt. 4","key":"10.1016\/j.sleep.2012.08.019_b0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/brain\/awh079","article-title":"Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome","volume":"127","author":"Stiasny-Kolster","year":"2004","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.sleep.2012.08.019_b0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.mehy.2007.01.037","article-title":"Can botulinum toxin put the restless legs syndrome to rest?","volume":"69","author":"Lim","year":"2007","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.sleep.2012.08.019_b0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5664\/jcsm.26586","article-title":"Botulinum toxin A: new hope for RLS?","volume":"2","author":"Kushida","year":"2006","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.sleep.2012.08.019_b0050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3109\/00207454.2011.602774","article-title":"Pilot trial of onabotulinumtoxina (Botox) in moderate to severe restless legs syndrome","volume":"121","author":"Agarwal","year":"2011","journal-title":"Int J Neurosci"},{"issue":"12","key":"10.1016\/j.sleep.2012.08.019_b0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/01.wnl.0000325994.93782.a1","article-title":"Double-blind, placebo-controlled, pilot trial of botulinum toxin A in restless legs syndrome","volume":"71","author":"Nahab","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.sleep.2012.08.019_b0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.sleep.2008.03.002","article-title":"Failure of botulinum toxin A to relieve restless legs syndrome","volume":"10","author":"Ghorayeb","year":"2009","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.sleep.2012.08.019_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5664\/jcsm.26585","article-title":"Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A","volume":"2","author":"Rotenberg","year":"2006","journal-title":"J Clin Sleep Med"},{"issue":"17","key":"10.1016\/j.sleep.2012.08.019_b0070","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain. A randomized double-blind crossover trial","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.sleep.2012.08.019_b0075","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","article-title":"Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain","volume":"64","author":"Ranoux","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.sleep.2012.08.019_b0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"issue":"2","key":"10.1016\/j.sleep.2012.08.019_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":"Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med"},{"issue":"8","key":"10.1016\/j.sleep.2012.08.019_b0090","first-page":"1200","article-title":"Clinical trials in restless legs syndrome-Recommendations of the European RLS Study Group (EURLSSG)","volume":"23","author":"Trenkwalder","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.sleep.2012.08.019_b0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"issue":"1\u20132","key":"10.1016\/j.sleep.2012.08.019_b0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2007.03.023","article-title":"Botulinum toxin A does not alter capsaicin-induced pain perception in human skin","volume":"260","author":"Schulte-Mattler","year":"2007","journal-title":"J Neurol Sci"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945712003346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945712003346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:09:06Z","timestamp":1761404946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945712003346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1389945712003346"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2012.08.019","relation":{},"ISSN":["1389-9457"],"issn-type":[{"type":"print","value":"1389-9457"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2012.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}